Industrial scale production of enhanced vaccine eggs for commercial influenza vaccine production trials
Influenza is an acute viral infection that occurs worldwide, is easily spread and has a high cost to society. Infection has a more serious effect on the young, elderly, pregnant women and persons with chronic diseases or weakened immune systems. To protect those at risk, the solution is vaccination, however, producing enough doses of vaccine in a cost-effective manner can be challenging. Additionally, vaccine manufacturers face considerable burdens such as increasing demand and speed of supply, especially in the current record high infection seasons. Furthermore, pricing pressures and escalating costs, as well as pandemic outbreaks, place heavy strains on manufacturing systems. A more efficient production process will lead to rapid responsiveness, greater coverage and a lessening of the costs to society with reduced infection rates. Influenza vaccines are grown in fertilised eggs and it can take two eggs to produce a single dose of vaccine. With 500 million doses of vaccine produced every year, this has dramatic cost implications across the whole vaccine production supply chain. VaXIMISER’s solution is a premium high yield egg specifically tailored to vaccine production to maximise vaccine growth.
VaXIMISER’s premium high yield vaccine egg will help to provide significantly more vaccine in less time and increase value for vaccine companies by improving production efficiency. Critical to industry adoption and commercialisation of an egg optimised to increase vaccine production is the scale-up, validation and adaptation of this technology to manufacturing conditions. We seek SIEF EDP support to enable the validation of our technology under commercial conditions and to support large scale pilot trials with leading vaccine companies. The industrial application of this invention will enhance the capacity to respond to disease outbreaks and will help to protect the world from the next pandemic.
For further information please contact:
Dr Andrew Bean, CSIRO: email@example.com